Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Virus Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Keratosis, Actinic 1Condylomata Acuminata 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Therapies, Investigational × Clear all
NCT02404389 2021-01-05

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Novartis

Phase 2 Completed
82 enrolled 16 charts
Dermatologic

Keratosis, Actinic

NCT02482428 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Novartis

Phase 2 Completed
88 enrolled 10 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡